Exchange: NASDAQ·Updated 07:30 PM EST
PTGX logo

PTGX Protagonist Therapeutics Inc

$121.40
$2.62
(2.11%)
Today
Closed $121.40
$0.00
(0.00%)
After Hours
Reported EarningsNov 5
Mkt Cap$7.92B
Vol600,730.00

About PTGX

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
42

Bearish Sentiment

How do you feel about PTGX?

shoc24
$PTGX is ranked #6 in healthcare quality with a score of 90. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.
Merlintrader
$PTGX — Four November bank conferences. Information only — not investment advice. More details in our hub.

Advertisement|Remove ads.